Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
ROCKVILLE, Md., Sept. 21, 2017 -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will participate in a fireside chat at the 2017 Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology on Wednesday, September 27th at 3:30PM Eastern.
Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator.
The fireside chat will be webcast live and may be accessed from the Event Calendar page of Sucampo's website at http://www.sucampo.com/investors/events-presentations/. A replay of the webcast will also be available on the Company's website for several days after the live event. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of highly specialized medicines. Sucampo has a late-stage pipeline of product candidates in clinical development for orphan disease areas, including VTS-270, a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1, a rare progressive genetic disorder. VTS-270 has also been granted breakthrough therapy designation in the U.S. Sucampo has an exclusive option for the North American rights to CPP-1X/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. The company has two marketed products – AMITIZA and RESCULA. For more information, please visit www.sucampo.com.
The Sucampo logo and the tagline, The Science of Innovation, are registered trademarks of Sucampo AG. AMITIZA is a registered trademark of Sucampo AG.
Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn (Sucampo Pharmaceuticals).
Twitter LinkedIn
Contact:
Sucampo Pharmaceuticals, Inc.
Silvia Taylor
Senior Vice President, Investor Relations and Corporate Affairs
1-240-223-3718
[email protected]
